$CRVO

BOGER JOSHUA S purchased $3.0M of CRVO (indirect holdings)

BOGER JOSHUA S purchased 955,414 indirectly-held shares of CervoMed Inc. (CRVO) at $3.14 ($3.00M total) on 2026-06-11.

Original reporting
SEC EDGAR · BOGER JOSHUA S
Published Jun 15, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:06 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CRVO
Neutral
medium confidence
Mentioned
$CRVO
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRVONeutralLow
01

Why it matters

A director and 10% owner purchased $3.0M of shares at $3.14/share (indirect holdings), with no pre-arranged 10b5-1 plan stated.

02

Market read

Traders may treat the insider buy as a mild sentiment input, but the filing alone is unlikely to drive a sustained repricing without additional company catalysts.

03

What to watch

The filing does not disclose any accompanying operational or clinical catalyst; without follow-on company news, traders may overreact to the insider signal.

Relevance 7/10Novelty 5/10Timing: filed 2026-06-15, transaction dated 2026-06-11

Background

The article is an SEC Form 4 insider transaction disclosure for CervoMed Inc. (CRVO).

Company-level read

Ticker impact

$CRVONeutralMedium confidence
Context

CervoMed director and 10% owner BOGER JOSHUA S bought 955,414 shares in an open-market transaction worth about $3.0M.

Expected impact

Likely limited near-term price impact; any effect would be sentiment-driven and modest.

Evidence & confidence

Form 4 provides a fresh, primary-source transaction, but insider buys without accompanying company-specific catalysts typically do not reset valuation expectations.

Market effects

No sector-wide implications disclosed; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The buy is indirect and not under a 10b5-1 plan, so it may reflect personal liquidity or estate structuring rather than a strong forward view.

Key entities

  • CervoMed Inc.

    Subject of the Form 4 insider transaction disclosure.

  • BOGER JOSHUA S

    Director and 10% owner who reported the open-market purchase.

Related articles

$CRVOMed

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

CervoMed Inc. (NASDAQ: CRVO) reported at AAIC 2026 new Phase 2b analyses for neflamapimod in dementia with Lewy bodies. The company said results support selecting 50 mg TID for a planned Phase 3, citing effects on CDR-SB, plasma pTau181 exposure, and MRI basal forebrain atrophy/connectivity. It also reported Phase 2 data for 80 mg BID meeting safety and PK objectives.

$CRVOMed

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

CervoMed (NASDAQ: CRVO) said it completed enrollment in a Phase 2a trial of oral p38a inhibitor neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA). The study enrolled 25 patients and includes 24 weeks of dosing plus a 12-week randomized placebo-controlled extension. Interim biomarker data are slated for CTAD in Nov 2026, with first biomarker and clinical data expected Q4 2026 and Q1 2027.

$CRVOMedAI 8/10

CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies

CervoMed (NASDAQ: CRVO) said it entered a definitive agreement for a private placement expected to raise about $10.5 million in upfront gross proceeds, extending its cash runway into Q2 2027, according to the company. Funds will support a strategic partnership to advance neflamapimod into Phase 3 for dementia with Lewy bodies. Over six months, it expects Phase 2a 24-week biomarker/clinical data and to start EXPERTS-ALS Phase 2a.

$CRVOMedAI 8/10

CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies

CervoMed (NASDAQ: CRVO) said it entered a definitive agreement for a private placement expected to raise about $10.5 million in upfront gross proceeds, with net proceeds extending its cash runway into Q2 2027. The company plans to prioritize securing a strategic partner to advance neflamapimod to Phase 3 for dementia with Lewy bodies. It also cited upcoming Phase 2a milestones in nfvPPA and ALS.